This suggests a distinct mechanism of action for TAZ in blood cancers, and indeed, it was shown that TAZ exerts its anti-cancer activity via down-regulation of MYC [38] and induction of miR-224 [40] in multiple myeloma (Figure 2B). The gene discussed is WWTR1; the disease is hematopoietic and lymphoid system neoplasm.